ESMO 2018 Congress: Scientific Articles & Press Releases

Interested in what happened during the ESMO 2018 Congress?

Read all our news here

Date Title Topic
24 Oct 2018 Carboplatin Plus Paclitaxel Respresents a New Standard of Care for Patients with Squamous Cell Carcinoma of the Anal Canal Gastrointestinal cancers - Anticancer agents & Biologic therapy
22 Oct 2018 Alectinib Provides Superior Outcomes Compared with Crizotinib in Asian Patients with Advanced ALK-positive NSCLC, with and without CNS Metastases Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
22 Oct 2018 Patients with HPV-positive oropharynx cancer should receive chemoradiation [ESMO 2018 Press Release] Head and neck cancers - Cancer Immunology and Immunotherapy
22 Oct 2018 Immunotherapy improves survival in metastatic or recurrent head and neck cancer [ESMO 2018 Press Release] Head and neck cancers - Cancer Immunology and Immunotherapy
22 Oct 2018 Major response to immunotherapy in early-stage mismatch repair deficient colon cancer [ESMO 2018 Press Release] Gastrointestinal cancers - Cancer Immunology and Immunotherapy
22 Oct 2018 B-F1RST Study Evaluates Blood-Based Tumour Mutational Burden as a Biomarker of Atezolizumab Activity in First-Line NSCLC Treatment Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
22 Oct 2018 Optimal Neo-Adjuvant Combination of Ipilimumab and Nivolumab Devised in High Risk Melanoma Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
22 Oct 2018 Immunotherapy may become new first line treatment in some metastatic colorectal cancers [ESMO 2018 Press Release] Gastrointestinal cancers
21 Oct 2018 Local radiotherapy improves survival in metastatic prostate cancer with low disease burden [ESMO 2018 Press Release] Genitourinary cancers
21 Oct 2018 Olaparib maintenance extends progression-free survival by estimated 3 years in advanced ovarian cancer [ESMO 2018 Press Release] Gynaecologic malignancies
21 Oct 2018 Avelumab plus axitinib significantly improve progression-free survival in untreated renal cell carcinoma [ESMO 2018 Press Release] Genitourinary cancers
21 Oct 2018 Entrectinib Is Effective Across NTRK Fusion Positive Solid Tumour Types Personalised medicine - Anticancer agents & Biologic therapy
21 Oct 2018 Erlotinib improves progression-free survival in early mutated non-small cell lung cancer [ESMO 2018 Press Release] Lung and other thoracic tumours
21 Oct 2018 Multi-strain probiotic reduces chemotherapy-induced diarrhoea [ESMO 2018 Press Release] Palliative and supportive care
21 Oct 2018 Drugs for treating breast cancer in women are effective and well tolerated in men [ESMO 2018 Press Release] Breast cancer - Cancer in Special Situations / Population